Cas:16285-74-8 4-Aminothieno[3,2-d]pyrimidine manufacturer & supplier

We serve Chemical Name:4-Aminothieno[3,2-d]pyrimidine CAS:16285-74-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-Aminothieno[3,2-d]pyrimidine

Chemical Name:4-Aminothieno[3,2-d]pyrimidine
CAS.NO:16285-74-8
Synonyms:4-Aminothieno[3,2-d]pyrimidine;4-Aminothieno[3,2-d]pyrimidine;thieno[3,2-d]pyrimidin-4-ylamine;4-Amino<3,2d>thienopyrimidin;4-Amino-thieno<3,2-d>pyrimidin;OSM-S-71
Molecular Formula:C6H5N3S
Molecular Weight:151.18900
HS Code:2934999090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:346.799ºC at 760 mmHg
Density:1.486g/cm3
Index of Refraction:1.785
PSA:80.04000
Exact Mass:151.02000
LogP:1.85470

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-Aminothieno[3,2-d]pyrimidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,OSM-S-71 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Aminothieno[3,2-d]pyrimidine Use and application,4-Amino&lt technical grade,usp/ep/jp grade.


Related News: In picking McNamara for the over-the-counter unit, GSK is once again de facto standing behind Walmsley as the captain of the remaining pharma, which will stay focused on therapeutics and vaccines, despite pressure from Elliott Management to shuffle its top ranks. 6-(4-fluorophenylamino)-1H-pyrimidine-2,4-dione manufacturers But when it came to deciding on whether Americans with compromised immune systems should get an extra dose of any COVID-19 vaccine, the CDC said it would need to wait for the FDA to give its regulatory thumbs up first. That could come either through amending its emergency use nods or awarding full approvals. 3,5-bis(methoxy)-N,N-dimethylbenzylamine suppliers Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful. 2,6-ditert-butyl-4-[(3,5-ditert-butyl-4-hydroxyphenyl)methylsulfinylmethyl]phenol vendor & factory.